# Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT00124644** · PHASE1 · TERMINATED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 30 (—)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** tipifarnib
- **PROCEDURE:** chemotherapy
- **PROCEDURE:** enzyme inhibitor therapy
- **PROCEDURE:** high-dose chemotherapy

## Key facts

- **NCT ID:** NCT00124644
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2007-12
- **Final completion:** 2008-01
- **Target enrollment:** 30 (—)
- **Why stopped:** Withdrawn due to "toxicity" problems
- **Last updated:** 2013-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124644, "Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00124644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*